$BLK

Meade Christopher J. sold $19.9M of BLK

Meade Christopher J. (General Counsel and CLO) sold 18,095 shares of BlackRock, Inc. (BLK) at an average of $1102.09 ($1101.99–$1102.80, $19.94M total) across 2 trades on 2026-07-16.

Original reporting
SEC EDGAR · Meade Christopher J.
Published Jul 17, 2026, 10:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 10:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLK
Neutral
medium confidence
Mentioned
$BLK
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLKNeutralLow
01

Why it matters

The newest concrete fact is the disclosed open-market sale totaling about $19.94M at roughly $1102/share, with holdings after the sale of 14,059 shares.

02

Market read

Traders may note insider selling as a sentiment datapoint, but there is no accompanying fundamental or regulatory catalyst in the text.

03

What to watch

The filing does not disclose motivations, whether sales were part of broader compensation/withholding activity, or whether other insiders made offsetting purchases.

Relevance 7/10Novelty 3/10Timing: after-hours/next-session read-through from a newly filed Form 4 (filed 2026-07-17)

Background

The article is a SEC Form 4 insider transaction for BlackRock, Inc. (BLK) by Meade Christopher J., General Counsel and CLO.

Company-level read

Ticker impact

$BLKNeutralMedium confidence
Context

BlackRock insider Meade Christopher J., General Counsel and CLO, sold about $19.94M of BLK shares via open-market transactions on 2026-07-16.

Expected impact

Likely limited near-term impact; any effect is more about signaling than new company information.

Evidence & confidence

The filing is a Form 4 insider transaction with disclosed trade size and price range, but it provides no new guidance, deal, or regulatory development.

Market effects

Minimal; large asset managers are not materially repriced from a single insider sale without accompanying corporate news.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs; the absence of a stated 10b5-1 plan does not necessarily imply negative expectations.

Key entities

  • BlackRock, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Meade Christopher J.

    General Counsel and CLO who sold BLK shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BLKHigh

BlackRock crypto ETFs grow 63%

BlackRock's crypto ETF assets grew 63% to $79.6 billion, though still 23% below 2025's peak. Institutional interest in Bitcoin and Ethereum ETFs is increasing, with a focus on regulated products. European MiCA regulations provide legal certainty for crypto assets. The growth impacts spot market liquidity but volatility remains moderate.

$BLKHighAI 8/10

At $15.49 Trillion, BlackRock AUM Equals 47.6% of U.S. Annualized GDP

BlackRock reported $15.49 trillion in AUM as of Sept. 30, equivalent to 47.6% of U.S. annualized GDP. The firm saw $205.466 billion in quarterly net inflows, up slightly from the prior year. Revenue rose 19% to $7.75 billion, with GAAP earnings per share increasing to $10.57. CEO Laurence Fink noted strong client inflows.

$HUMMed

Humana’s $2.8 bn BlackRock deal follows Medicare Advantage ratings recovery

Humana (HUM) agreed to a $2.8 bn deal with BlackRock, restructuring ownership of 150 CenterWell clinics. BlackRock acquires WCAS's majority stake, with Humana retaining minority ownership. The deal reduces Humana's balance sheet obligations. Humana's Medicare Advantage star ratings improved, potentially increasing 2028 bonus payments to $4.8 bn, per Evercore ISI. S&P affirmed Humana's BBB rating but maintained a negative outlook.

$HUMMedAI 9/10

Seniors at About 150 CenterWell Clinics Face New Majority Owner as BlackRock Replaces Private Equity Backer

Humana announced that BlackRock's HPS Investment Partners will acquire Welsh Carson's stake in about 150 CenterWell clinics, valued at $2.8B. The deal, expected to close in Q4 2026, will make BlackRock the majority owner, with CenterWell retaining a minority stake and operational control. Humana stated patient care will remain unchanged, and the deal is not expected to materially affect its 2026 earnings guidance.